New schizophrenia pill shows promise in early trial
NCT ID NCT00862992
First seen Jan 06, 2026 · Last updated May 16, 2026 · Updated 22 times
Summary
This study tested an experimental drug called MP-214 in 34 adults with schizophrenia. Participants took one of three doses daily for 14 days to see if it was safe and could help control symptoms. The goal was to measure side effects, drug levels in the blood, and any improvement in symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hoyu Hospital
Kure, Hiroshima, Japan
Conditions
Explore the condition pages connected to this study.